Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.12Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 25, 2025
|% Change Since: -13.99%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with notable progress in clinical trials, increased cash reserves, and strategic advancements offset by increased losses and expenses. While the company's financial health shows challenges, the advancements in drug development and potential future catalysts provide optimism.Company Guidance
During the Corvus Pharmaceuticals fourth quarter and full year 2024 business update, the company provided various financial and clinical metrics. Research and development expenses increased to $5.2 million in Q4 2024 from $3.2 million in Q4 2023, largely due to socalitinib clinical trial costs. The full-year R&D expenses were $19.4 million compared to $16.5 million in 2023. The company reported a net loss of $12.1 million in Q4 2024, up from $6.7 million in the prior year, impacted by non-cash losses related to Angel Pharmaceuticals and warrant liabilities. Full-year net loss was $63.3 million, compared to $27.0 million in 2023. As of December 31, 2024, cash and securities totaled $52 million, with the potential to increase by $41 million if all warrants are exercised. The company anticipates that their cash will support operations until Q1 2026. Clinically, socalitinib showed a 39% objective response rate in a Phase 1 trial for T-cell lymphoma and promising results in atopic dermatitis trials. Future plans include further trials for socalitinib across autoimmune and oncology indications, with significant data releases expected throughout 2025.Increased Cash Position
Corvus Pharmaceuticals ended 2024 with cash, cash equivalents, and marketable securities totaling $52 million, compared to $27.1 million at the end of 2023, providing cash runway into the first quarter of 2026.
Successful Clinical Trials with Socalitinib
Reported a 39% objective response rate and 26% complete response rate from the Phase 1 trial of socalitinib in relapsed T-cell lymphoma. Significant responses in atopic dermatitis with no patients achieving IGA zero or one or EASI 75 in the placebo group.
Phase 3 Trial Enrollment for Socalitinib
Enrolling a registrational Phase 3 trial of socalitinib in patients with relapsed peripheral T-cell lymphoma, with significant experience being applied to other programs.
Interim Data from Atopic Dermatitis Trial
Favorable safety and efficacy profile observed in Phase 1 trial for atopic dermatitis, with significant responses compared to placebo.
NIH Trial Initiation for ALPS
Initiated a Phase 2 trial of socalitinib in patients with autoimmune lymphoproliferative syndrome (ALPS) in collaboration with NIH.
---
CRVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 25, 2025 | $3.93 | $3.35 | -14.76% |
| Nov 12, 2024 | $8.69 | $8.87 | +2.07% |
| Aug 06, 2024 | $3.00 | $3.29 | +9.67% |
| May 06, 2024 | $1.91 | $1.68 | -12.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Corvus Pharmaceuticals Inc (CRVS) report earnings?
Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Corvus Pharmaceuticals Inc (CRVS) earnings time?
Corvus Pharmaceuticals Inc (CRVS) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRVS EPS forecast?
CRVS EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---